tbuckley/cabot-search huggingface dataset:
Contents
Authors: Harry Quigley, Florent Aptel, Philippe Denis, Bingsong Wang, Lisandro Sakata, David Friedman, Yiong-Huak Chan, Mingguang He, Raghavan Lavanya, Tien-Yin Wong, Tin Aung, Alan Rotchford, Anthony King, Kata Miha ´ltz, Kinga Kra ´nitz, Ja ´nos Ne ´meth, Z Nagy, Douglas Covert, Christopher Henry, Steven Koenig, Liliana Werner, Marie-Jose ´tassignon, Brian Zaugg, Veva De Groot, Jos Rozema, Ronald Klein, Kristine Lee, Ronald Gangnon, Barbara Klein, Chee-Tin Lee, Emma Gayton, Joline Beulens, Declan Flanagan, Amanda Adler, Fleur Goezinne, Ellen Heij, T Berendschot, Nayyirih Tahzib, Diana Cals, Albert Liem, Igor Lundqvist, Fred Hendrikse, Chieko Shiragami, Fumio Shiraga, Hidetaka Yamaji, Kouki Fukuda, Mai Takagishi, Misako Morita, Takehiro Co
Journal: Ophthalmology (2009)
Instructions in Laboratory Work in Bacteriology for Students in Professional Schools
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEWS
Journal: British Journal of Dermatology (1966)

British Journal of DermatologyVolume 78, Issue 4 p. 246-246 BOOK REVIEWS First published: April 1966 https://doi.org/10.1111/j.1365-2133.1966.tb12216.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Book reviewed in this article: Skin Diseases in Arabian Countries. M. El Zawahry. A Short Textbook of Venereology. R. D. Catterall (1965) Proceedings of the World Forum on Syphilis and other Treponematoses. U.S. Department of Health and Welfare, Public Health Service (1964). Volume78, Issue4April 1966Pages 246-246 RelatedInformation
A Phase II Trial of Ofatumumab In Subjects with Waldenstrom's Macroglobulinemia.
Authors: Richard R. Furman, Herbert Eradat, Julie C. Switzky, Suzanne R. Hayman, Craig C. Hofmeister, Nathalie A. Avignon, John P. Leonard, Morton Coleman, Qiming Liao, Damini N. Shah, Stephanie Brownell-Buttich, Steen Lisby, Thomas S. Lin
Journal: Blood (2010)
Risk of rash and stomatitis with everolimus, a mammalian target of rapamycin (mTOR) inhibitor: A meta-analysis.
Authors: M. K. Ramirez-Fort, S. Wu, M. E. Lacouture
Journal: Journal of Clinical Oncology (2011)

e19556 Background: Everolimus, an mTOR inhibitor, is indicated for the treatment of patients with subependymal giant cell astrocytoma associated with tuberous sclerosis and advanced renal cell carcinoma. Mucocutaneous toxicities are the most commonly reported, and are assessed in oncology clinical trials as an adverse event based on the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTC AE) grading system for dermatologic toxicities. We systematically investigated the overall incidence and risk of rash and stomatitis in patients receiving everolimus. Methods: Relevant publications were identified from PubMed database (2001 to 2011). Eligible studies for analysis were limited to prospective Phase II-III clinical trials with 10mg per day dosing and the use of the NCI-CTC AE grading system, version 3.0. Incidence, relative risk (RR), and 95% confidence intervals were calculated using random-effects or fixed-effects models based on the heterogeneity of included studies. Results: A total of 1,592 patients from 11 clinical trials were available for analysis. The overall incidences of all-grade and high-grade (grade ≥3) rash were 35.8% (95% CI: 28.4-43.9) and 1.3% (95% CI: 0.7-2.2), respectively. The overall incidences of all-grade and high-grade stomatitis were 55.7 % (CI: 48.0-63.2) and 5.5% (95% CI: 4.1-7.4). Everolimus was associated with significantly increased risk of all-grade rash and all-grade stomatitis (RR=2.74, 95% CI: 1.29-5.80; P<0.01 and RR=4.81, 95% CI: 2.87-8.05; P<0.001) in comparison with controls. The risk of high-grade rash was increased (RR=2.93, 95% CI: 0.50-17.14; p=0.23). The risk of high-grade stomatitis was significantly increased (RR=4.67, 95% CI: 1.38-15.81; P=0.013). Conclusions: Cancer patients treated with everolimus are at significant risk for developing mucocutaneous toxicities. Although the newest NCI-CTC AE version, 3.0, has made improvements by categorizing rash using more descriptive terms, these terms were rarely used in the studies analyzed. A more accurate grading system is urgently needed, in addition to further studies for prevention and treatment of these untoward toxicities.
Pharmacotherapy
Journal: Gut (2002)

Serotonergic modulation of visceral sensation: upper gutSelective serotonin reuptake inhibitors (SSRIs), and 5-HT 4 , 5-HT 1P , and 5-HT 1A receptor agonists all have an effect on postprandial tone in the stomach and therefore have therapeutic potential for the treatment of visceral hypersensitivity.Further clinical evaluation of these agents should focus on collecting data at the time of peak postprandial symptoms, which occurs approximately 75 minutes after a meal, and data collection should continue for up to four hours.
Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST)
Authors: A. E. Epstein
Journal: JAMA (1993)

<h3>Objective.</h3> —To test the hypothesis that in survivors of myocardial infarction, the suppression of ventricular premature depolarizations improves survival free of cardiac arrest and arrhythmic death. <h3>Design.</h3> —International, prospective, multicenter, randomized, placebo-controlled trial. <h3>Setting.</h3> —University and community hospitals. <h3>Patients.</h3> —A total of 3549 patients with myocardial infarction and left ventricular dysfunction. <h3>Intervention.</h3> —Administration of encainide, flecainide, moricizine, or placebo to suppress ventricular premature depolarizations. <h3>Main Outcome Measures.</h3> —Overall survival and survival free of cardiac arrest or arrhythmic death were compared in patients randomized to long-term, active antiarrhythmic drug therapy vs corresponding placebo, using the stratified log rank statistic. <h3>Results.</h3> —At 1 year from the time of randomization to blinded therapy, 95% of placebo-treated patients vs 90% of active drug—treated patients remained alive (<i>P</i>=.0006). Similarly, at 1 year, 96% of placebo-treated patients vs 93% of active drug—treated patients remained free of cardiac arrest or arrhythmic death (<i>P</i>=.003). <h3>Conclusions.</h3> —The suppression of asymptomatic or mildly symptomatic ventricular arrhythmias after myocardial infarction does not improve survival and can increase mortality. Treatment strategies designed solely to suppress these arrhythmias should no longer be followed. (<i>JAMA</i>. 1993;270:2451-2455)
THE NON-PERMANENCE OF INEBRIETY CURES EXEMPLIFIED.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MEDICINE AND SOCIOLOGY
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Grading financial toxicity based upon its impact on health-related quality of life (HRQol).
Authors: Jonas A. De Souza, Kristen Wroblewski, Bonnie J. Yap, Jeremy O'Connor, Bruce Brockstein, Mai Tuyet Pho, Mark J. Ratain, Christopher Daugherty, David Cella
Journal: Journal of Clinical Oncology (2015)

6618 Background: Financial toxicity (FT) is an important patient-centered outcome. The impact of this toxicity on patients' HRQoL is not well known. We hypothesized that FT can be graded based on statistically significant and clinically meaningful decreases in HRQoL. Methods: FT was assessed by the quantitative COST (COmprehensive Score for financial Toxicity). Gradations of FT's impact on HRQoL were based on established conventions for clinically meaningful small, medium and large effect sizes (e.s.) for the FACT-G HRQoL instrument. The optimal COST cutoff scores for FT grades were determined by ROC curve analyses maximizing the sum of the sensitivity and specificity in comparison with normative FACT-G values for the general adult population. Following FACIT standards, higher FT was represented by lower COST values. Demographics, tumor type, length of disease, chemotherapy use, resource utilization, HRQoL, and symptoms (EORTC QLQ-C30 symptom scales) were collected. Data were analyzed using Pearson correlations, linear regression, and chi-square tests. Results: A total of 233 patients who had completed at least 3 months of chemotherapy were assessed. The correlation between the COST and FACT-G was r = 0.42, p < .001. ROC curve analyses produced optimal COST FT grades (G) as follows: G0 ≥ 26 (n = 99 patients, 42%), G1: ≥ 14-25 (n = 71, 31%) and G2: > 0-14 (n = 58, 25%). Five patients (2%) had scores of 0 (G3). On multivariate analyses, pts with G0 had no impact of FT in their HRQoL; G1 had a statistically significant small and meaningful e.s. difference compared to G0 (0.26, p < .05); G2 had a statistically significant and medium e.s. (0.47, p < .001); G3 had a significant and clinically meaningful large e.s. (0.99, p < .005). There was a significant relationship between FT (grades 1-3) and younger age (p < .01), non-Caucasians ( < .05), less than a college degree ( < .01), unemployment (.001), Medicaid ( < .05), and lower income ( < .001). Conclusions: We developed a FT grading system based on clinically meaningful changes in HRQoL. There were 134 (58%) patients with Grades 1-3 FT. Financial distress as it relates to HRQoL is a meaningful event that can be objectively measured, and should be included in the assessment of patient-centered outcomes.
NEW INTESTINAL PARASITES: A PLEA FOR MORE CAREFUL FECAL EXAMINATIONS
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Virological characterization of patients with chronic hepatitis C and failure to a glecaprevir/pibrentasvir or voxilaprevir/ velpatasvir/sofosbuvir treatment in the international shared collaboration
Authors: Adolfo de Salazar, Julia Dietz, Velia Chiara Di Maio, Slim Fourati, Beat Müllhaupt, Stefania Paolucci, Joaquin Cabezas, Rudolf E. Stauber, Nicola Coppola, Juan Arenas, Christiana Graf, Miguel Jiménez-Pérez, Elisabetta Degasperi, Juan Manuel Pascasio, Maria Paola Callegaro, Johannes Vermehren, Jose Miguel Rosales Zabal, Giovanni Battista Gaeta, Miguel Garcia-Deltoro, Heinz Zoller, Massimo Puoti, Christoph Berg, Mark Douglas, Jean-Michel Pawlotsky, Anita Howe, Federico Garcia Garcia, Francesca Ceccherini Silberstein, Christoph Sarrazin
Journal: Journal of Hepatology (2020)
Newspapers Comment on Labeling
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
3. Prevention or Delay of Type 2 Diabetes: <i>Standards of Medical Care in Diabetes—2019</i>
Journal: Diabetes Care (2018)

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Defending normativism
Authors: Steven Hrotic
Journal: Behavioral and Brain Sciences (2011)

Abstract Elqayam &amp; Evans (E&amp;E) argue that evaluative normativism leads to unacceptable research biases, and should be avoided. Though it is stipulated that the particular biases they discuss are cause for concern, this argument should not be generalized. The boundary between evaluative and goal-directed “directive” norms is difficult to define, and normative assumptions are an integral part of academic progress; moreover, the biases that result may have beneficial potential.
NEONATAL BILIRUBIN AND THE BRAIN
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PNEUMONIA MORTALITY OF PHYSICIANS.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Thankfulness Unlimited
Authors: Thomas J O'Donnell
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Luminal and basal subtyping of prostate cancer.
Authors: Felix Yi-Chung Feng, Shuang Zhao, Seiwon Laura Chang, Nicholas Erho, Jonathan Lehrer, Mohammed Alshalalfa, Matthew R. Cooperberg, Won Kim, Charles J. Ryan, Robert B. Den, Stephen J. Freedland, Edwin M. Posadas, Eric A. Klein, Elai Davicioni, Ashley Ross, Edward M. Schaeffer, Paul L. Nguyen, Peter Carroll, Jeffrey Karnes, Daniel Eidelberg Spratt
Journal: Journal of Clinical Oncology (2017)
Forbidden Fruits
Authors: S. Levin
Journal: JAMA (1967)

<h3>To the Editor:—</h3> The forbidden fruit a pomegranate? No, sir. I think Dr. Samuel Bigg of Canada (<b>199</b>:343, 1967) is wrong. God was not concerned with the sexual desire of the first couple and with the high estrogen ("begetter of mad desire") content of pomegranates. Remember that the Great Surgeon had just elaborated Eve from Adam's suprarenal gland (<i>Med Proc</i><b>7</b>:223, 1961) and could not risk them eating anything which might raise their postoperative blood pressure, such as bananas, for example, which are known to have high catecholamine and noradrenaline contents. But they ate the forbidden bananas and, though this was not lethal (Genesis 2:7), it disturbed the Great Surgeon sufficiently for Him to meet out punishment, and we have suffered the consequences. Of course, had the silly girl not listened to that snake in the grass in the first place, the world would not be in the